CAPR logo

CAPR Capricor Therapeutics, Inc.

NASDAQ · Biotechnology · Healthcare

$8.03
-0.38 (-4.52%)

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered …

Market Cap: $465.03Mwww.capricor.com

Price

$7.45-2.49%
$3.85$14.35$24.84$35.34
Jul 2025Aug 2026

Social Signal Score

38
5d
—
30d
43
3 mentions
+0.0%
60d
42
5 mentions
+0.0%
90d
28
13 mentions
+0.0%
news: 13

Analyst Ratings

10 analysts
Buyconsensus
Strong Buy 0Buy 9Hold 1Sell 0Strong Sell 0
Avg price target$12.7+58.2%
Low $3.5Median $7High $25
Current Consensus

52-week range

$3.85$35.34
Last close
$7.45
Off 52w high
-78.9%
200-day average
$23.19
vs 200-day
-67.9%

Compare with other stocks off their highs

Revenue

$0.00-100.00%
$0.00$4.03M$8.06M$12.09M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-2.13
$-2.21–$-2.01
7 analysts
FY2026
$-2.46
$-2.84–$-0.87
8 analysts
FY2027
$-1.44
$-3.23–$-0.13
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Linda Marbán
Sector
Healthcare
Industry
Biotechnology
Employees
231
Beta
0.53
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-0.18
www.capricor.com